var data={"title":"Pyomyositis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Pyomyositis</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/pyomyositis/contributors\" class=\"contributor contributor_credentials\">Larry M Baddour, MD, FIDSA, FAHA</a></dd><dd><a href=\"https://www.uptodate.com/contents/pyomyositis/contributors\" class=\"contributor contributor_credentials\">Anuwat Keerasuntornpong, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pyomyositis/contributors\" class=\"contributor contributor_credentials\">Daniel J Sexton, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pyomyositis/contributors\" class=\"contributor contributor_credentials\">Elinor L Baron, MD, DTMH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/pyomyositis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;May 10, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pyomyositis is a purulent infection of skeletal muscle that arises from hematogenous spread, usually with abscess formation [<a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/1\" class=\"abstract_t\">1</a>]. The clinical approach to pyomyositis will be reviewed here. Other soft tissue infections such as clostridial myonecrosis and necrotizing fasciitis are discussed separately. (See <a href=\"topic.htm?path=clostridial-myonecrosis\" class=\"medical medical_review\">&quot;Clostridial myonecrosis&quot;</a> and <a href=\"topic.htm?path=necrotizing-soft-tissue-infections\" class=\"medical medical_review\">&quot;Necrotizing soft tissue infections&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pyomyositis is classically an infection of the tropics, although it has been recognized in temperate climates with increasing frequency [<a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/2-8\" class=\"abstract_t\">2-8</a>]. Tropical pyomyositis primarily occurs in two age groups: children (ages 2 to 5) and adults (ages 20 to 45), while the majority of temperate pyomyositis cases occurs in adults. Males appear to be more commonly affected than females. Most patients with tropical pyomyositis are otherwise healthy without underlying comorbidities, while most patients in temperate regions are immunocompromised or have other serious underlying conditions.</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Predisposing factors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Predisposing factors for pyomyositis include immunodeficiency, trauma, injection drug use, concurrent infection, and malnutrition [<a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/2,9-13\" class=\"abstract_t\">2,9-13</a>].</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h3\">Immunodeficiency</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Immunodeficiency has been implicated in the development of pyomyositis in both temperate and tropical climates. Forms of immunodeficiency associated with pyomyositis include HIV infection, diabetes mellitus, malignancy, cirrhosis, renal insufficiency, organ transplantation, and administration of immunosuppressive agents [<a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/2,14\" class=\"abstract_t\">2,14</a>].</p><p>HIV is a particularly important risk factor [<a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/2,4,7,12,15-19\" class=\"abstract_t\">2,4,7,12,15-19</a>]. A case-control series in Uganda demonstrated a significant association between pyomyositis and HIV infection [<a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/7\" class=\"abstract_t\">7</a>]. In a review of 98 cases in North America, about half of pyomyositis patients with underlying medical conditions were seropositive for HIV [<a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/4\" class=\"abstract_t\">4</a>]. The mechanism of HIV infection in the predisposition to pyomyositis is unclear; factors may include immune compromise, primary HIV myopathy, antiretroviral therapy, and increased rates of staphylococcal carriage [<a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/2,7,18,19\" class=\"abstract_t\">2,7,18,19</a>].</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h3\">Trauma</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Trauma has been postulated as a predisposing factor for pyomyositis; about 25 to 50 percent of patients with pyomyositis report a history of trauma. In addition, pyomyositis has been described in temperate regions among athletes performing vigorous exercise, suggesting the potential role of minor muscle damage in the pathogenesis of the disease [<a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/20-26\" class=\"abstract_t\">20-26</a>]. Development of infection may be related to hematoma formation or increased muscle perfusion due to trauma, providing additional iron to the muscle bed for favorable bacterial growth conditions [<a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/3,6\" class=\"abstract_t\">3,6</a>].</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h3\">Injection drug use</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Injection drug use has been associated with pyomyositis-induced bacteremia. Local injection site infection and abscess extension into muscle tissue should not be confused with true pyomyositis caused by hematogenous seeding of muscle groups distant from injection sites [<a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/27-30\" class=\"abstract_t\">27-30</a>].</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h3\">Concurrent infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Toxocariasis has been associated with the subsequent development of pyomyositis, perhaps because of predisposing muscle damage and impaired local immunity [<a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/31\" class=\"abstract_t\">31</a>]. Underlying skin conditions predisposing to secondary bacteremia, such as varicella infection, have also been described [<a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/2,32\" class=\"abstract_t\">2,32</a>].</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">MICROBIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Staphylococcus aureus</em> is the most common cause of pyomyositis; it causes up to 90 percent of tropical cases and up to 75 percent of temperate cases [<a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/2,4,6,9-11,13,33\" class=\"abstract_t\">2,4,6,9-11,13,33</a>]. Methicillin-resistant <em>S. aureus</em> (MRSA), including community-acquired strains, is also an increasingly important pathogen [<a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/34-37\" class=\"abstract_t\">34-37</a>]. In a retrospective review of 29 adults with pyomyositis, MRSA comprised 25 percent of cases due to <em>S. aureus</em> [<a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/36\" class=\"abstract_t\">36</a>]. Group A streptococci is the second most common pathogen.</p><p>Less common causes include non-group A streptococci, pneumococci, and gram-negative enteric bacilli [<a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/2,5,10,13,27,38-40\" class=\"abstract_t\">2,5,10,13,27,38-40</a>]. <em>Escherichia coli </em>pyomyositis is an emerging infection among patients with hematologic malignancy [<a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/41\" class=\"abstract_t\">41</a>]. It is usually caused by members of <em>E. coli</em> ST131, a cause of fluoroquinolone-resistant, extended-spectrum beta-lactamase (ESBL)-positive <em>E. coli</em> infection worldwide. Meningococcal pyomyositis has been described in a case report [<a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/42\" class=\"abstract_t\">42</a>].</p><p>Mycobacterial pyomyositis has also been reported [<a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/40,43-47\" class=\"abstract_t\">40,43-47</a>]. Pyomyositis can also be polymicrobial, particularly in diabetic patients [<a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/2\" class=\"abstract_t\">2</a>].</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pyomyositis presents with fever and pain with cramping localized to a single muscle group. The disease occurs most often in the lower extremity (sites include the thigh, calf, and gluteal muscles), but any muscle group can be involved, including the iliopsoas, pelvic, trunk, paraspinal, and upper extremity muscles [<a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/2,48\" class=\"abstract_t\">2,48</a>]. Multifocal infection with involvement of more than one muscle group may be observed in up to 20 percent of cases [<a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/2,49\" class=\"abstract_t\">2,49</a>].</p><p>Pyomyositis can be divided into three clinical stages [<a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/33\" class=\"abstract_t\">33</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Stage 1 is characterized by crampy local muscle pain, swelling, and low-grade fever. Mild leukocytosis and induration of the affected muscle may be present. A deep abscess may not be discretely palpable, but the muscle may have a &quot;woody&quot; texture on palpation. Fluctuation is not present, and aspiration of the muscle will not yield purulent material. Only 2 percent of patients present at this stage.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Stage 2 occurs 10 to 21 days after the initial onset of symptoms and is characterized by fever, exquisite muscle tenderness, and edema. A frank abscess may be clinically apparent, and aspiration of the affected muscle typically yields pus [<a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/50\" class=\"abstract_t\">50</a>]. Marked leukocytosis is usually present. More than 90 percent of the patients present at this suppurative stage.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Stage 3 is characterized by systemic toxicity. The affected muscle is fluctuant. Complications of <em>S. aureus</em> bacteremia such as septic shock, endocarditis, septic emboli, pneumonia, pericarditis, septic arthritis, brain abscess, and acute renal failure can occur [<a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/51,52\" class=\"abstract_t\">51,52</a>]. Rhabdomyolysis has also been described [<a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/39\" class=\"abstract_t\">39</a>].</p><p/><p>The course of pyomyositis is variable. Although most patients present with stage 2 or 3 disease, some experience a more indolent course; a delay in diagnosis in such cases may result in involvement of multiple muscle groups, requiring prolonged therapy. Recurrent infection is rare but has been described in immunocompromised individuals [<a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/2\" class=\"abstract_t\">2</a>]. Mortality due to pyomyositis was reported to be as high as 10 percent in one retrospective cohort study [<a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/53\" class=\"abstract_t\">53</a>].</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pyomyositis may be confused with muscle strain, contusion, hematoma, cellulitis, deep vein thrombosis, osteomyelitis, septic arthritis, or neoplasm. It must also be distinguished from clostridial myonecrosis, necrotizing fasciitis, spontaneous gangrenous myositis, diabetic muscle infarction, septic arthritis, and other forms of myositis (<a href=\"image.htm?imageKey=ID%2F68260\" class=\"graphic graphic_table graphicRef68260 \">table 1</a>). (See <a href=\"topic.htm?path=clostridial-myonecrosis\" class=\"medical medical_review\">&quot;Clostridial myonecrosis&quot;</a> and <a href=\"topic.htm?path=necrotizing-soft-tissue-infections\" class=\"medical medical_review\">&quot;Necrotizing soft tissue infections&quot;</a> and <a href=\"topic.htm?path=diabetic-muscle-infarction\" class=\"medical medical_review\">&quot;Diabetic muscle infarction&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Tools for diagnosis of pyomyositis include radiography, cultures, and laboratory data.</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Radiography</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Radiographic imaging is the most useful tool for diagnosing pyomyositis, defining the site(s) of infection, and for ruling out other entities. If available, magnetic resonance imaging (MRI) is the optimal imaging technique [<a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/1,54\" class=\"abstract_t\">1,54</a>]. It is highly sensitive for muscle inflammation, even prior to the formation of a frank abscess, and can demonstrate the extent of involvement in the tissues. MRI findings include diffuse muscle enlargement with an increase in signal intensity on T2-weighted images and intermediate signal on T1-weighted images as well as single or multiple intramuscular abscesses with a peripheral enhancement [<a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/9,54-56\" class=\"abstract_t\">9,54-56</a>].</p><p>If MRI is not available, computed tomography (CT) is helpful for detecting muscle swelling and well-delineated areas of fluid attenuation that display rim enhancement with contrast, as well as for radiographic-guided drainage of purulent material [<a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/57\" class=\"abstract_t\">57</a>]. Ultrasonography is also a potentially useful diagnostic and therapeutic tool, particularly during the purulent stage of infection when it may reveal diffuse muscle hyperechogenicity with or without localized hypoechogenicity and diffuse hyperemia (<a href=\"image.htm?imageKey=RADIOL%2F93854\" class=\"graphic graphic_diagnosticimage graphicRef93854 \">image 1</a>) [<a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/58,59\" class=\"abstract_t\">58,59</a>].</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Cultures</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Bacteriologic diagnosis can be made by cultures of drainage specimens. Diagnostic drainage prior to antibiotic therapy is helpful for obtaining optimal microbiologic data and susceptibility testing to direct specific therapy.</p><p>Blood cultures are positive in up to 10 percent of tropical cases and 35 percent of temperate cases [<a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/1,2,6\" class=\"abstract_t\">1,2,6</a>]. Given that the pathogenesis of pyomyositis likely involves bloodstream infection, patients with pyomyositis should be evaluated for the presence of additional complications of bacteremia. Rarely, pyomyositis has been described in association with endocarditis [<a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/29,60\" class=\"abstract_t\">29,60</a>]. In the setting of systemic toxicity, at least two sets of blood cultures should be obtained prior to initiation of antimicrobial therapy; presence of bacteremia should prompt a careful clinical assessment for signs and symptoms of infective endocarditis. (See <a href=\"topic.htm?path=clinical-approach-to-staphylococcus-aureus-bacteremia-in-adults\" class=\"medical medical_review\">&quot;Clinical approach to Staphylococcus aureus bacteremia in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">Laboratory data</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Nonspecific laboratory findings include leukocytosis with left shift and elevated inflammatory markers (erythrocyte sedimentation rate and C-reactive protein). Eosinophilia should raise suspicion for a concomitant parasitic infection [<a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/61\" class=\"abstract_t\">61</a>]. Counterintuitively, creatine kinase levels are often normal [<a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/2,5\" class=\"abstract_t\">2,5</a>].</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although stage 1 pyomyositis can be treated with antibiotics alone, most patients present with stage 2 or 3 disease and therefore require both antibiotics and drainage for definitive management [<a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/33\" class=\"abstract_t\">33</a>].</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">Drainage</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Image-guided percutaneous drainage is an option for many patients and can be useful both to secure a microbiologic diagnosis early in patient evaluation and as a therapeutic measure when combined with antimicrobial therapy. Percutaneous drainage is often computed tomography (CT) guided, but, in selected patients, an ultrasound (US)-guided procedure is an option. In the setting of deep infection or extensive muscle involvement with significant necrosis, however, surgical intervention may be required. Regardless of the type of drainage procedure done, antimicrobial therapy should be initiated without delay in patients who present with systemic toxicity.</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h2\">Antibiotics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For immunocompetent individuals, initial empiric parenteral antibiotic therapy should be directed against staphylococci, including methicillin-resistant <em>S. aureus</em> (MRSA) and streptococci [<a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/1\" class=\"abstract_t\">1</a>]. Parenteral agents for treatment are outlined in the Table (<a href=\"image.htm?imageKey=ID%2F77419\" class=\"graphic graphic_table graphicRef77419 \">table 2</a>). (See <a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-epidemiology#H8\" class=\"medical medical_review\">&quot;Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Epidemiology&quot;, section on 'Risk factors'</a> and <a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia\" class=\"medical medical_review\">&quot;Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia&quot;</a>.)</p><p>For immunocompromised individuals, broad antibiotic coverage for gram-positive, gram-negative, and anaerobic organisms should be administered. In such circumstances, <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> may be combined with a broad-spectrum regimen that has activity against gram negatives and anaerobes (<a href=\"image.htm?imageKey=ID%2F64708\" class=\"graphic graphic_table graphicRef64708 \">table 3</a>).</p><p><a href=\"topic.htm?path=clindamycin-drug-information\" class=\"drug drug_general\">Clindamycin</a> is sometimes included in the antibiotic regimen for severe infections due to <em>S. aureus</em> or beta-hemolytic streptococci because it has several unique characteristics. It suppresses synthesis of bacterial toxins and penicillin-binding proteins, which are involved in cell wall synthesis and degradation, it has a longer post-antibiotic effect compared with beta-lactams, and it is not affected by bacterial inoculum size or stage of growth. It is not known whether the addition of clindamycin as adjunctive therapy can reduce morbidity and mortality rates in severely ill patients with pyomyositis due to these organisms. We do not routinely use it for this purpose in the absence of necrotizing infection or concern for toxic shock syndrome. (See <a href=\"topic.htm?path=staphylococcal-toxic-shock-syndrome#H23\" class=\"medical medical_review\">&quot;Staphylococcal toxic shock syndrome&quot;, section on 'Antibiotic therapy'</a> and <a href=\"topic.htm?path=necrotizing-soft-tissue-infections#H24\" class=\"medical medical_review\">&quot;Necrotizing soft tissue infections&quot;, section on 'Antibiotic therapy'</a>.)</p><p>The duration of antimicrobial therapy should be tailored to clinical and radiographic improvement. Three to four weeks of parenteral therapy is usually sufficient, although patients with extensive, multifocal, or poorly drained infection may warrant longer courses of therapy [<a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/2,4\" class=\"abstract_t\">2,4</a>]. The course of therapy for patients with other sequelae of bacteremia (such as endocarditis or osteomyelitis) should be adjusted based on the nature of infection at these other sites [<a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/6\" class=\"abstract_t\">6</a>]. In rare cases of infections caused by mycobacteria, the nature and duration of treatment should be tailored to the microbiologic isolate.</p><p class=\"headingAnchor\" id=\"H3119550134\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-skin-and-soft-tissue-infections\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Skin and soft tissue infections&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pyomyositis is a purulent infection of skeletal muscle that arises from hematogenous spread, usually with abscess formation. It is classically an infection of the tropics, although it has been recognized in temperate climates with increasing frequency. (See <a href=\"#H2\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Risk factors for pyomyositis include immunodeficiency (particularly HIV infection), trauma, injection drug use, concurrent infection, and malnutrition. (See <a href=\"#H3\" class=\"local\">'Predisposing factors'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>Staphylococcus aureus</em> is the most common cause of pyomyositis; it causes up to 90 percent of tropical cases and up to 75 percent of temperate cases. Methicillin-resistant <em>S. aureus</em>, including community-acquired strains, is also an increasingly important pathogen. (See <a href=\"#H8\" class=\"local\">'Microbiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pyomyositis presents with fever and pain with cramping localized to a single muscle group. It develops most often in the lower extremity (sites include the thigh, calf, and gluteal muscles), but any muscle group can be involved, including the iliopsoas, pelvic, trunk, paraspinal, and upper extremity muscles. The clinical stages of pyomyositis are outlined above. (See <a href=\"#H9\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Radiographic imaging with magnetic resonance imaging is the most useful tool for diagnosing pyomyositis, defining the site(s) of infection, and for ruling out other entities. Bacteriologic diagnosis can be made by cultures of drainage specimens <span class=\"nowrap\">and/or</span> blood. Nonspecific laboratory findings include leukocytosis and elevated inflammatory markers; creatine kinase levels are often normal [<a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/2,5\" class=\"abstract_t\">2,5</a>]. (See <a href=\"#H11\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Although stage 1 pyomyositis can be treated with antibiotics alone, most patients present with stage 2 or 3 disease and therefore require both antibiotics and drainage for definitive management. (See <a href=\"#H15\" class=\"local\">'Treatment'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For immunocompetent individuals, initial empiric parenteral antibiotic therapy should be directed against staphylococci and streptococci. For immunocompromised individuals, broad antibiotic coverage for gram-positive, gram-negative, and anaerobic organisms should be considered. Reasonable antibiotic regimens are outlined in the Tables (<a href=\"image.htm?imageKey=ID%2F77419\" class=\"graphic graphic_table graphicRef77419 \">table 2</a> and <a href=\"image.htm?imageKey=ID%2F64708\" class=\"graphic graphic_table graphicRef64708 \">table 3</a>). (See <a href=\"#H17\" class=\"local\">'Antibiotics'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/1\" class=\"nounderline abstract_t\">Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis 2014; 59:147.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/2\" class=\"nounderline abstract_t\">Crum NF. Bacterial pyomyositis in the United States. Am J Med 2004; 117:420.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/3\" class=\"nounderline abstract_t\">Gibson RK, Rosenthal SJ, Lukert BP. Pyomyositis. Increasing recognition in temperate climates. Am J Med 1984; 77:768.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/4\" class=\"nounderline abstract_t\">Christin L, Sarosi GA. Pyomyositis in North America: case reports and review. Clin Infect Dis 1992; 15:668.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/5\" class=\"nounderline abstract_t\">Bickels J, Ben-Sira L, Kessler A, Wientroub S. Primary pyomyositis. J Bone Joint Surg Am 2002; 84-A:2277.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/6\" class=\"nounderline abstract_t\">Chauhan S, Jain S, Varma S, Chauhan SS. Tropical pyomyositis (myositis tropicans): current perspective. Postgrad Med J 2004; 80:267.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/7\" class=\"nounderline abstract_t\">Horn CV, Master S. Pyomyositis tropicans in Uganda. East Afr Med J 1968; 45:463.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/8\" class=\"nounderline abstract_t\">Moriarty P, Leung C, Walsh M, Nourse C. Increasing pyomyositis presentations among children in Queensland, Australia. Pediatr Infect Dis J 2015; 34:1.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/9\" class=\"nounderline abstract_t\">Small LN, Ross JJ. Tropical and temperate pyomyositis. Infect Dis Clin North Am 2005; 19:981.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/10\" class=\"nounderline abstract_t\">Widrow CA, Kellie SM, Saltzman BR, Mathur-Wagh U. Pyomyositis in patients with the human immunodeficiency virus: an unusual form of disseminated bacterial infection. Am J Med 1991; 91:129.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/11\" class=\"nounderline abstract_t\">Schwartzman WA, Lambertus MW, Kennedy CA, Goetz MB. Staphylococcal pyomyositis in patients infected by the human immunodeficiency virus. Am J Med 1991; 90:595.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/12\" class=\"nounderline abstract_t\">Rodgers WB, Yodlowski ML, Mintzer CM. Pyomyositis in patients who have the human immunodeficiency virus. Case report and review of the literature. J Bone Joint Surg Am 1993; 75:588.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/13\" class=\"nounderline abstract_t\">Gomez-Reino JJ, Aznar JJ, Pablos JL, et al. Nontropical pyomyositis in adults. Semin Arthritis Rheum 1994; 23:396.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/14\" class=\"nounderline abstract_t\">Belsky DS, Teates CD, Hartman ML. Case report: diabetes mellitus as a predisposing factor in the development of pyomyositis. Am J Med Sci 1994; 308:251.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/15\" class=\"nounderline abstract_t\">Ansalonl L, Acaye GL, Re MC. High HIV seroprevalence among patients with pyomyositis in northern Uganda. Trop Med Int Health 1996; 1:210.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/16\" class=\"nounderline abstract_t\">Blumberg HM, Stephens DS. Pyomyositis and human immunodeficiency virus infection. South Med J 1990; 83:1092.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/17\" class=\"nounderline abstract_t\">Jellis JE. Viral infections: musculoskeletal infection in the human immunodeficiency virus (HIV) infected patient. Baillieres Clin Rheumatol 1995; 9:121.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/18\" class=\"nounderline abstract_t\">Holbrook KA, Klein RS, Hartel D, et al. Staphylococcus aureus nasal colonization in HIV-seropositive and HIV-seronegative drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:301.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/19\" class=\"nounderline abstract_t\">Miller M, Cespedes C, Vavagiakis P, et al. Staphylococcus aureus colonization in a community sample of HIV-infected and HIV-uninfected drug users. Eur J Clin Microbiol Infect Dis 2003; 22:463.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/20\" class=\"nounderline abstract_t\">Burkhart BG, Hamson KR. Pyomyositis in a 69-year-old tennis player. Am J Orthop (Belle Mead NJ) 2003; 32:562.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/21\" class=\"nounderline abstract_t\">Chusid MJ, Hill WC, Bevan JA, Sty JR. Proteus pyomyositis of the piriformis muscle in a swimmer. Clin Infect Dis 1998; 26:194.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/22\" class=\"nounderline abstract_t\">Jayoussi R, Bialik V, Eyal A, et al. Pyomyositis caused by vigorous exercise in a boy. Acta Paediatr 1995; 84:226.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/23\" class=\"nounderline abstract_t\">King RJ, Laugharne D, Kerslake RW, Holdsworth BJ. Primary obturator pyomyositis: a diagnostic challenge. J Bone Joint Surg Br 2003; 85:895.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/24\" class=\"nounderline abstract_t\">Koutures CG, Savoia M, Pedowitz RA. Staphylococcus aureus thigh pyomyositis in a collegiate swimmer. Clin J Sport Med 2000; 10:297.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/25\" class=\"nounderline abstract_t\">Meehan J, Grose C, Soper RT, Kimura K. Pyomyositis in an adolescent female athlete. J Pediatr Surg 1995; 30:127.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/26\" class=\"nounderline abstract_t\">Viani RM, Bromberg K, Bradley JS. Obturator internus muscle abscess in children: report of seven cases and review. Clin Infect Dis 1999; 28:117.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/27\" class=\"nounderline abstract_t\">Hsueh PR, Hsiue TR, Hsieh WC. Pyomyositis in intravenous drug abusers: report of a unique case and review of the literature. Clin Infect Dis 1996; 22:858.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/28\" class=\"nounderline abstract_t\">Ebright JR, Pieper B. Skin and soft tissue infections in injection drug users. Infect Dis Clin North Am 2002; 16:697.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/29\" class=\"nounderline abstract_t\">Lo TS, Mooers MG, Wright LJ. Pyomyositis complicating acute bacterial endocarditis in an intravenous drug user. N Engl J Med 2000; 342:1614.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/30\" class=\"nounderline abstract_t\">Crossley M. Temperate pyomyositis in an injecting drug misuser. A difficult diagnosis in a difficult patient. Emerg Med J 2003; 20:299.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/31\" class=\"nounderline abstract_t\">Rayes AA, Nobre V, Teixeira DM, et al. Tropical pyomyositis and human toxocariasis: a clinical and experimental study. Am J Med 2000; 109:422.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/32\" class=\"nounderline abstract_t\">Gubbay AJ, Isaacs D. Pyomyositis in children. Pediatr Infect Dis J 2000; 19:1009.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/33\" class=\"nounderline abstract_t\">Chiedozi LC. Pyomyositis. Review of 205 cases in 112 patients. Am J Surg 1979; 137:255.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/34\" class=\"nounderline abstract_t\">Mart&iacute;nez-Aguilar G, Avalos-Mishaan A, Hulten K, et al. Community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus musculoskeletal infections in children. Pediatr Infect Dis J 2004; 23:701.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/35\" class=\"nounderline abstract_t\">Ruiz ME, Yohannes S, Wladyka CG. Pyomyositis caused by methicillin-resistant Staphylococcus aureus. N Engl J Med 2005; 352:1488.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/36\" class=\"nounderline abstract_t\">Zalavras CG, Rigopoulos N, Poultsides L, Patzakis MJ. Increased oxacillin resistance in thigh pyomyositis in diabetic patients. Clin Orthop Relat Res 2008; 466:1405.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/37\" class=\"nounderline abstract_t\">Fowler A, Mackay A. Community-acquired methicillin-resistant Staphylococcus aureus pyomyositis in an intravenous drug user. J Med Microbiol 2006; 55:123.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/38\" class=\"nounderline abstract_t\">Wang TK, Wong SS, Woo PC. Two cases of pyomyositis caused by Klebsiella pneumoniae and review of the literature. Eur J Clin Microbiol Infect Dis 2001; 20:576.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/39\" class=\"nounderline abstract_t\">Falasca GF, Reginato AJ. The spectrum of myositis and rhabdomyolysis associated with bacterial infection. J Rheumatol 1994; 21:1932.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/40\" class=\"nounderline abstract_t\">Lawn SD, Bicanic TA, Macallan DC. Pyomyositis and cutaneous abscesses due to Mycobacterium avium: an immune reconstitution manifestation in a patient with AIDS. Clin Infect Dis 2004; 38:461.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/41\" class=\"nounderline abstract_t\">Vigil KJ, Johnson JR, Johnston BD, et al. Escherichia coli Pyomyositis: an emerging infectious disease among patients with hematologic malignancies. Clin Infect Dis 2010; 50:374.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/42\" class=\"nounderline abstract_t\">Barakat MT, Gajurel K, Fischer K, et al. A Case of Meningococcal Pyomyositis in an Otherwise Healthy Adult. Open Forum Infect Dis 2016.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/43\" class=\"nounderline abstract_t\">Chu CK, Yang TL, Tan CT. Tuberculous pyomyositis of the temporal muscle in a nonimmunocompromised woman: diagnosis by sonography. J Laryngol Otol 2004; 118:59.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/44\" class=\"nounderline abstract_t\">Wang JY, Lee LN, Hsueh PR, et al. Tuberculous myositis: a rare but existing clinical entity. Rheumatology (Oxford) 2003; 42:836.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/45\" class=\"nounderline abstract_t\">Ahmed J, Homans J. Tuberculosis pyomyosits of the soleus muscle in a fifteen-year-old boy. Pediatr Infect Dis J 2002; 21:1169.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/46\" class=\"nounderline abstract_t\">Johnson DW, Herzig KA. Isolated tuberculous pyomyositis in a renal transplant patient. Nephrol Dial Transplant 2000; 15:743.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/47\" class=\"nounderline abstract_t\">Shih JY, Hsueh PR, Chang YL, et al. Pyomyositis due to Mycobacterium haemophilum in a patient with polymyositis and long-term steroid use. Clin Infect Dis 1998; 26:505.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/48\" class=\"nounderline abstract_t\">Shepherd JJ. Tropical myositis: is it an entity and what is its cause? Lancet 1983; 2:1240.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/49\" class=\"nounderline abstract_t\">Niamane R, Jalal O, El Ghazi M, et al. Multifocal pyomyositis in an immunocompetent patient. Joint Bone Spine 2004; 71:595.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/50\" class=\"nounderline abstract_t\">Peckett WR, Butler-Manuel A, Apthorp LA. Pyomyositis of the iliacus muscle in a child. J Bone Joint Surg Br 2001; 83:103.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/51\" class=\"nounderline abstract_t\">Nourse C, Starr M, Munckhof W. Community-acquired methicillin-resistant Staphylococcus aureus causes severe disseminated infection and deep venous thrombosis in children: literature review and recommendations for management. J Paediatr Child Health 2007; 43:656.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/52\" class=\"nounderline abstract_t\">Lin MY, Rezai K, Schwartz DN. Septic pulmonary emboli and bacteremia associated with deep tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2008; 46:1553.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/53\" class=\"nounderline abstract_t\">Sharma A, Kumar S, Wanchu A, et al. Clinical characteristics and predictors of mortality in 67 patients with primary pyomyositis: a study from North India. Clin Rheumatol 2010; 29:45.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/54\" class=\"nounderline abstract_t\">Theodorou SJ, Theodorou DJ, Resnick D. MR imaging findings of pyogenic bacterial myositis (pyomyositis) in patients with local muscle trauma: illustrative cases. Emerg Radiol 2007; 14:89.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/55\" class=\"nounderline abstract_t\">Mitsionis GI, Manoudis GN, Lykissas MG, et al. Pyomyositis in children: early diagnosis and treatment. J Pediatr Surg 2009; 44:2173.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/56\" class=\"nounderline abstract_t\">Bertrand SL, Lincoln ED, Prohaska MG. Primary pyomyositis of the pelvis in children: a retrospective review of 8 cases. Orthopedics 2011; 34:e832.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/57\" class=\"nounderline abstract_t\">Struk DW, Munk PL, Lee MJ, et al. Imaging of soft tissue infections. Radiol Clin North Am 2001; 39:277.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/58\" class=\"nounderline abstract_t\">Quillin SP, McAlister WH. Rapidly progressive pyomyositis. Diagnosis by repeat sonography. J Ultrasound Med 1991; 10:181.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/59\" class=\"nounderline abstract_t\">Tichter A, Riley DC. Emergency department diagnosis of a quadriceps intramuscular loculated abscess/pyomyositis using dynamic compression bedside ultrasonography. Crit Ultrasound J 2013; 5:3.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/60\" class=\"nounderline abstract_t\">Hsu WC, Hsu JY, Chen MY, Liang CC. Obturator internus pyomyositis manifested as sciatica in a patient with subacute bacterial endocarditis: A rare case report. Medicine (Baltimore) 2016; 95:e4340.</a></li><li><a href=\"https://www.uptodate.com/contents/pyomyositis/abstract/61\" class=\"nounderline abstract_t\">Scharschmidt TJ, Weiner SD, Myers JP. Bacterial Pyomyositis. Curr Infect Dis Rep 2004; 6:393.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 7669 Version 13.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H18\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">EPIDEMIOLOGY</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Predisposing factors</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">- Immunodeficiency</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">- Trauma</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">- Injection drug use</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">- Concurrent infection</a></li></ul></li></ul></li><li><a href=\"#H8\" id=\"outline-link-H8\">MICROBIOLOGY</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">CLINICAL MANIFESTATIONS</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">DIAGNOSIS</a><ul><li><a href=\"#H12\" id=\"outline-link-H12\">Radiography</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">Cultures</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">Laboratory data</a></li></ul></li><li><a href=\"#H15\" id=\"outline-link-H15\">TREATMENT</a><ul><li><a href=\"#H16\" id=\"outline-link-H16\">Drainage</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">Antibiotics</a></li></ul></li><li><a href=\"#H3119550134\" id=\"outline-link-H3119550134\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H18\" id=\"outline-link-H18\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/7669|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=RADIOL/93854\" class=\"graphic graphic_diagnosticimage\">- Imaging pyomyositis</a></li></ul></li><li><div id=\"ID/7669|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ID/68260\" class=\"graphic graphic_table\">- Differential diagnosis myositis and fasciitis</a></li><li><a href=\"image.htm?imageKey=ID/77419\" class=\"graphic graphic_table\">- Abx therapy pyomyositis</a></li><li><a href=\"image.htm?imageKey=ID/64708\" class=\"graphic graphic_table\">- Immunocompromised pyo rx</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-approach-to-staphylococcus-aureus-bacteremia-in-adults\" class=\"medical medical_review\">Clinical approach to Staphylococcus aureus bacteremia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clostridial-myonecrosis\" class=\"medical medical_review\">Clostridial myonecrosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diabetic-muscle-infarction\" class=\"medical medical_review\">Diabetic muscle infarction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-epidemiology\" class=\"medical medical_review\">Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Epidemiology</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=methicillin-resistant-staphylococcus-aureus-mrsa-in-adults-treatment-of-bacteremia\" class=\"medical medical_review\">Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=necrotizing-soft-tissue-infections\" class=\"medical medical_review\">Necrotizing soft tissue infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-skin-and-soft-tissue-infections\" class=\"medical medical_society_guidelines\">Society guideline links: Skin and soft tissue infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=staphylococcal-toxic-shock-syndrome\" class=\"medical medical_review\">Staphylococcal toxic shock syndrome</a></li></ul></div></div>","javascript":null}